美国癌症中心尽管对病人和员工有利,却由于计费风险而缓慢地采用非皮下免疫疗法。 U.S. cancer centers slowly adopt subcutaneous immunotherapy due to billing risks, despite patient and staff benefits.

癌症中心正在谨慎地采用低于皮皮的免疫性检查站抑制剂,优先通过永久性J编码进行稳定偿还,而不是不顾病人和工作人员的利益而迅速推出。 Cancer centers are cautiously adopting subcutaneous immune checkpoint inhibitors, prioritizing stable reimbursement through permanent J-codes over rapid rollout despite patient and staff benefits. 虽然这些配方提高了方便性,缩短了注入时间,并消除了IV类用品,从而降低了成本,但是由于对诸如Pembrocroizumab等高成本药物的不确定性和资金风险进行计费,各机构拖延了全面实施。 While these formulations improve convenience, reduce infusion times, and lower costs by eliminating IV supplies, institutions delay full implementation due to billing uncertainties and financial risks tied to high-cost drugs like pembrolizumab. 灵活的处方模式允许选择病人开关,有些系统通过电子医疗记录更新简化了采用。 Flexible prescribing models allow select patient switches, and some systems streamline adoption via electronic medical record updates. 今后的挑战包括《减少通货膨胀法》的2028年定价规则和生物类同的四类药物,这可能使长期战略复杂化。 Future challenges include the Inflation Reduction Act’s 2028 pricing rules and biosimilar IV drugs, which may complicate long-term strategy. 尽管护理方面对人工注射的需求感到关切,但越来越多的使用得到了患者满意度和业务成果的支持。 Despite nursing concerns over manual injection demands, growing use is supported by patient satisfaction and operational gains.